BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-87@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Hoffmann-La Roche — Atezolizumab [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study Evaluating the Efficacy and
  Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for 
 Participants With HER2-Positive Breast Cancer at High Risk of Recurrence F
 ollowing Preoperative Therapy.\nSource: https://clinicaltrials.gov/study/N
 CT04873362\nhttps://catalystbrief.girapphe.com/e/87?lang=en\nNot investmen
 t advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/87?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
